These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Investigational drugs for the treatment of acute myocardial infarction: focus on antiplatelet and anticoagulant agents. Yandrapalli S; Andries G; Gupta S; Dajani AR; Aronow WS Expert Opin Investig Drugs; 2019 Mar; 28(3):223-234. PubMed ID: 30580647 [TBL] [Abstract][Full Text] [Related]
29. Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors. Steffel J; Lüscher TF J Cardiovasc Med (Hagerstown); 2009 Aug; 10(8):616-23. PubMed ID: 19561526 [TBL] [Abstract][Full Text] [Related]
30. Ticagrelor, a platelet aggregation inhibitor for the potential prevention and treatment of arterial thrombosis and acute coronary syndromes. Doggrell SA IDrugs; 2009 May; 12(5):309-17. PubMed ID: 19431096 [TBL] [Abstract][Full Text] [Related]
31. Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis. Bauer KA Am J Orthop (Belle Mead NJ); 2002 Nov; 31(11 Suppl):4-10. PubMed ID: 12463577 [TBL] [Abstract][Full Text] [Related]
32. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI. Ferguson JJ; Wilson JM; Diez J Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162 [TBL] [Abstract][Full Text] [Related]
33. New oral anticoagulants in atrial fibrillation. Turpie AG Eur Heart J; 2008 Jan; 29(2):155-65. PubMed ID: 18096568 [TBL] [Abstract][Full Text] [Related]
35. The safety of fondaparinux for the prevention and treatment of venous thromboembolism. Turpie AG Expert Opin Drug Saf; 2005 Jul; 4(4):707-21. PubMed ID: 16011449 [TBL] [Abstract][Full Text] [Related]
36. Emerging anticoagulants: mechanism of action and future potential. Klement P; Rak J Vnitr Lek; 2006 Mar; 52 Suppl 1():119-22. PubMed ID: 16637459 [TBL] [Abstract][Full Text] [Related]
37. Antiplatelet intervention in acute coronary syndrome. Arora RR; Rai F Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648 [TBL] [Abstract][Full Text] [Related]
38. Cardiovascular risk associated with interruption of antiplatelet and oral anticoagulation therapy. Ferreira JS; Gil VM Rev Port Cardiol; 2009; 28(7-8):845-58. PubMed ID: 19894663 [TBL] [Abstract][Full Text] [Related]
39. Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding. May AE; Geisler T; Gawaz M Thromb Haemost; 2008 Mar; 99(3):487-93. PubMed ID: 18327396 [TBL] [Abstract][Full Text] [Related]
40. Historical Hallmarks of Anticoagulation and Antiplatelet Agents. Tsoucalas G; Chevallier J; Karamanou M; Papaioannou T; Sgantzos M; Androutsos G Curr Pharm Des; 2016; 22(13):1857-61. PubMed ID: 26750139 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]